NCT03982316: TeleBMM

Telehealth Behavioral Migraine Management

Completed NA Results posted Last updated 11 March 2026

What this trial tests

NA trial testing Telehealth Behavioral Migraine Management in Migraine in 20 participants. Completed in 30 October 2024.

Timeline

15 September 2020

Primary endpoint
15 September 2024

30 October 2024

Quick facts

Lead sponsor	Albert Einstein College of Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	15 September 2020
Primary completion	15 September 2024
Estimated completion	30 October 2024
Sites	1 location across United States

Drugs / interventions tested

• Telehealth Behavioral Migraine Management
• Education Modules

Conditions studied

• Migraine — all drugs for Migraine →

Sponsor

Albert Einstein College of Medicine

Who can join

Adults 18 to 65, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Feasibility of TeleBMM Primary · Week 0 through Week 12

Feasibility of the study will be based on patient adherence to the protocol. The number of treatment components participants complete (out of 20) will be tabulated. It is hypothesized that at least half of the participants will attend all four study sessions and complete all three self-guided modules. Dropouts will be included in the analysis. Results will be summarized using basic descriptive statistics.

Group	Value	95% CI
Telehealth Behavioral Migraine Management	14.2	± 5.6

Change in Quality of Life (Migraine Specific) Secondary · Change from Pre-treatment (Week 0) to Post-treatment (Week 12)

Change in Migraine-related disability over the prior 4 week period was assessed based on Version 2.1 of the Migraine Specific Quality of Life Questionnaire (MSQ). The MSQ is a 14-item survey assessing quality of life in people with migraine. Responses from the 14 Items (which are reverse-coded) encompassing three domains (Role Restriction - 7 items; Role Prevention - 4 items; and Emotional Function - 3 items) were rated on a 6-point scale ranging from 1 ("None of the time") to 6 ("All of the time"). Raw scores were summed and linearly converted to a 0-100 scale wherein higher scores are associ

Group	Value	95% CI
Telehealth Behavioral Migraine Management	9.3	± 27.6
Education Modules	-11.4	± 14.4

Change in Headache Frequency Secondary · Change from Week 0 to Week 12

Participants were asked to complete a daily headache diary, on which each 7 day week they denoted whether they have had a headache attack. Slope change from Week 0 to Week 12 is reported as a proportion of headache days/month (ranging from 0-1) and is summarized by study arm.

Group	Value	95% CI
Telehealth Behavioral Migraine Management	.13	± .004
Education Control	.18	± .017

Sponsor's own description

This project aims to develop the protocol and obtain feasibility and acceptability information for Telehealth Behavioral Migraine Management in a single-arm pre-post pilot study. The investigator and study team aim to recruit 20 people with migraine from the Montefiore Headache Center in the Bronx New York. Participants will receive the 12-week protocol including a mobile app headache diary, an online patient manual with interactive vignettes, 4 50-minute telehealth sessions, and 3 15-minute check-ins.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Evaluating an Abbreviated Version of Mindfulness-Based Cognitive Therapy Delivered via Telephone or Videoconferencing Compared to Enhanced Usual Care-Treatment for Migraine and Mood (TEAM-M) Study: Protocol for a Three-Arm Multisite Randomized Controlled Feasibility Trial.
   Siwik CJ, Tankha H, Hill JD, Visvanathan P, et al · · 2026 · PMID 42247631 · DOI 10.2196/93627